Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3‐ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission-Reference-Cited by-同舟云学术

Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3‐ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission

Published:2020-10-06 Issue:1 Volume:106 Page:64-71
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur. J. Haematol.

Author:

Ofran Yishai¹²^ORCID,Leiba Ronit³,Frisch Avraham¹,Horesh Nurit¹,Henig Israel¹,Yehudai‐Ofir Dana¹²,Moshe Yakir⁴,Neaman Miriam⁴,Ganzel Chezi⁵^ORCID,Gal‐Rabinovich Kinneret¹,Hellmann Ilana⁶,Weinstein Vladimir⁷,Berger Tamar⁸,Wolach Ofir⁸

Affiliation:

1. Department of Hematology and Bone Marrow Transplantation Rambam Health Care Campus Haifa Israel

2. The Ruth and Bruce Rappaport Faculty of Medicine Technion, Haifa Israel

3. Department of Statistics Rambam Health Care Campus Haifa Israel

4. Department of Hematology and Bone Marrow Transplantation Tel Aviv Sourasky Medical Center Tel Aviv Israel

5. Department of Hematology Shaare Zedek Medical Center Jerusalem Israel

6. Hematology Unit Meir Medical Center Kfar Saba Israel

7. Department of Hematology Hadassah Medical Center Jerusalem Israel

8. Hematology Institute Davidoff Cancer CenterRabin Medical Center Petah Tikva Israel

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13518

Reference20 articles.

1. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3Mutation

2. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

3. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

4. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

5. Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment;Hematology Reports;2023-05-24

2. Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches;OncoTargets and Therapy;2022-11

3. Which FLT3 Inhibitor for Treatment of AML?;Current Treatment Options in Oncology;2022-03